Related Experiment Video
Updated: Mar 17, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Statins for the prevention of contrast-induced acute kidney injury
Jill Vanmassenhove1, Raymond Vanholder, Norbert Lameire
1Renal Division, Ghent University Hospital, Ghent, Belgium.
Insights
It is too early to use statins for preventing contrast-induced acute kidney injury (CI-AKI). Current guidelines recommend hydration and low-osmolar contrast media for CI-AKI prevention.
Area of Science:
- Nephrology
- Cardiology
- Radiology
Background:
- Contrast-induced acute kidney injury (CI-AKI) is a significant concern in patients undergoing procedures involving intravascular contrast media.
- Statins have been investigated for their potential role in preventing CI-AKI.
Purpose of the Study:
- To review recent meta-analyses on statin use for CI-AKI prevention.
- To provide recommendations for clinical practice regarding statin use in CI-AKI prevention.
Main Methods:
- Systematic review of meta-analyses published between January 2015 and April 2016.
- Analysis of heterogeneity in study populations, treatment protocols, and CI-AKI definitions across studies.
Main Results:
- Nine meta-analyses were identified, revealing significant heterogeneity.
- Inconsistent definitions of CI-AKI and limited analysis of clinically meaningful endpoints like hospital stay and adverse events were noted.
Conclusions:
- Current evidence is insufficient to recommend routine preprocedural statin use for CI-AKI prevention.
- Adequate hydration and use of low-osmolar contrast media remain the primary preventive strategies.
- Further well-designed randomized controlled trials are needed to establish the risk-benefit profile of statins for CI-AKI prevention.
Purpose Of Review:
To highlight the most recently published meta-analyses on the role of statins in the prevention of contrast-induced acute kidney injury (CI-AKI) and to formulate recommendations for clinical practice.
Recent Findings:
Nine meta-analyses were published on this topic from January 2015 to April 2016. Significant clinical heterogeneity between studies, regarding study population, treatment protocol, concomitant preventive strategies or dosage and duration of statin therapy was observed. In addition, the definition of CI-AKI was not uniform throughout all studies, and a number of other clinically meaningful endpoints, such as length of hospital stay in patients who developed CI-AKI, as well as adverse events, were rarely analyzed.
Summary:
Despite some promising results, it is premature to adapt the existing guidelines and implement the preprocedural use of statins in daily clinical practice. At present, low volumes of iso-osmolar or low-osmolar intravascular contrast and adequate intravascular hydration in high-risk patients remain the cornerstone for the prevention of CI-AKI. There is a need for additional well designed randomized controlled trials to clarify these issues and assess the risk vs benefit of statin use for the purpose of CI-AKI prevention.
More Related Videos
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Kidney Injury I: Introduction
Cardiac Catheterization I: Pre-Procedure Overview
Imaging Studies VII: Vascular Imaging

